Go Premium

Notifications

TipRanks

Notifications

Tag: RNA

Total 194 Posts

Analysts’ Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)

October 4, 2024

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO – Research Report), Avidity Biosciences (RNA – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments.

DocGo (DCGO)

Stifel Nicolaus analyst David Grossman maintained a Buy rating on DocGo today and set a price target of $6.50. The company’s shares closed last Thursday at $3.15, close to its 52-week low of $2.75.

According to TipRanks.com, Grossman is a 4-star analyst with an average return of 6.2% and a 57.3% success rate. Grossman covers the Technology sector, focusing on stocks such as International Business Machines, Exlservice Holdings, and DXC Technology.

DocGo has an analyst consensus of Strong Buy, with a price target consensus of $6.30.

See Insiders’ Hot Stocks on TipRanks >>

Avidity Biosciences (RNA)

Avidity Biosciences received a Buy rating and a $56.00 price target from TD Cowen analyst Ritu Baral today. The company’s shares closed last Thursday at $47.05, close to its 52-week high of $49.41.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 9.1% and a 44.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Milestone Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avidity Biosciences with a $63.70 average price target, representing a 34.3% upside. In a report issued on September 24, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $59.00 price target.

Ultragenyx Pharmaceutical (RARE)

In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $127.00. The company’s shares closed last Thursday at $53.66.

According to TipRanks.com, Ha is a 3-star analyst with an average return of 2.4% and a 43.3% success rate. Ha covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Rocket Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $84.80 average price target, which is a 53.6% upside from current levels. In a report issued on October 1, TD Cowen also maintained a Buy rating on the stock with a $61.00 price target.

Read More on DCGO:

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and Avidity Biosciences (RNA)

October 4, 2024

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Halozyme (HALO – Research Report) and Avidity Biosciences (RNA – Research Report) with bullish sentiments.

Halozyme (HALO)

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Halozyme yesterday and set a price target of $64.00. The company’s shares closed last Thursday at $60.43, close to its 52-week high of $65.53.

According to TipRanks.com, Purohit has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 31.6% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arcutis Biotherapeutics, and BioMarin Pharmaceutical.

Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $60.89, implying a 4.8% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $72.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Avidity Biosciences (RNA)

In a report released yesterday, Gena Wang from Barclays initiated coverage with a Buy rating on Avidity Biosciences and a price target of $63.00. The company’s shares closed last Thursday at $47.05, close to its 52-week high of $49.41.

According to TipRanks.com, Wang is a 4-star analyst with an average return of 6.9% and a 42.7% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and BioMarin Pharmaceutical.

Avidity Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $63.70, representing a 34.3% upside. In a report issued on September 24, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $59.00 price target.

Read More on HALO:

Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Johnson & Johnson (JNJ) and Avidity Biosciences (RNA)

October 4, 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on LivaNova (LIVN – Research Report), Johnson & Johnson (JNJ – Research Report) and Avidity Biosciences (RNA – Research Report).

LivaNova (LIVN)

Goldman Sachs analyst David Roman initiated coverage with a Buy rating on LivaNova today and set a price target of $65.00. The company’s shares closed last Thursday at $53.21.

According to TipRanks.com, Roman is a 3-star analyst with an average return of 4.7% and a 68.0% success rate. Roman covers the Healthcare sector, focusing on stocks such as Baxter International, Edwards Lifesciences, and Tandem Diabetes Care.

Currently, the analyst consensus on LivaNova is a Strong Buy with an average price target of $70.57.

See Insiders’ Hot Stocks on TipRanks >>

Johnson & Johnson (JNJ)

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $163.00. The company’s shares closed last Thursday at $160.50.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 10.7% and a 62.4% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Bausch + Lomb Corporation, and Inspire Medical Systems.

Johnson & Johnson has an analyst consensus of Moderate Buy, with a price target consensus of $171.83.

Avidity Biosciences (RNA)

In a report released yesterday, Yanan Zhu from Wells Fargo assigned a Buy rating to Avidity Biosciences, with a price target of $75.00. The company’s shares closed last Thursday at $47.05, close to its 52-week high of $49.41.

According to TipRanks.com, Zhu is a 4-star analyst with an average return of 10.4% and a 33.1% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avidity Biosciences with a $63.70 average price target, implying a 34.3% upside from current levels. In a report issued on September 24, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $59.00 price target.

Read More on LIVN: